TP53 and glioblastoma: The results shown in Figure 5A indicated that, compared with 6 cycles of TMZ chemotherapy, more than 6 cycles of TMZ resulted in more than 2 times and about 1.8 times longer mOS in GBM patients with wild-type p53 and mutant p53, respectively (p53 wild-type GBM patients: 46.90 months vs. 16.80 months, HR = 3.93, 95% CI: 1.06 ~ 14.60, P = 0.002; p53 mutant GBM patients: 29.00 months vs. 15.95 months, HR = 2.57, 95% CI:1.47 ~ 4.49, P < 0.001).